Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NewPLACE: MOR202 in anti-PLA2R antibody positive membranous nephropathy
2020-002985-15Phase 2Unknown
- Sponsor
- MorphoSys AG
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of felzartamab in membranous glomerulonephritis (MGN) (2 arms), sponsored by MorphoSys AG. Primary endpoint: Percent change of anti-PLA2R antibody levels. Status: unknown.
02
Drugs
felzartamab
03
Conditions
membranous glomerulonephritis (MGN)
Beyond the preview
Go deeper on 2020-002985-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002985-15.